Imane H. S. Benyamina, Obadia V. Nyongole, Fransia A. Mushi, Daniel W. Kitua, Aubrey Otieno, Ally H. Mwanga
{"title":"在接受抗逆转录病毒治疗的艾滋病毒感染者中调查恼人的下尿路症状:患病率、影响因素和生活质量影响","authors":"Imane H. S. Benyamina, Obadia V. Nyongole, Fransia A. Mushi, Daniel W. Kitua, Aubrey Otieno, Ally H. Mwanga","doi":"10.1186/s12301-023-00394-y","DOIUrl":null,"url":null,"abstract":"Abstract Background Urological complications are not uncommon among people living with HIV and are often the initial clinical manifestation of HIV and AIDS. These complications, when presenting with bothersome lower urinary tract symptoms (LUTS), can significantly impact the Quality of life (QoL) of affected individuals. We, therefore, conducted a study aiming at determining the prevalence of bothersome LUTS, identifying factors influencing the severity of these symptoms, and examining their influence on the QoL among people living with HIV on antiretroviral treatment (ART). Methods A cross-sectional study was conducted among randomly selected adult HIV-positive patients who attended the Care and Treatment Center at Muhimbili National Hospital, located in Dar es Salaam, Tanzania, from September 2021 to February 2022. Data was collected using a questionnaire that incorporated the American version of the International Prostate Symptom Score (IPSS). The IPSS was utilized to assess the severity of LUTS and their influence on the QoL. Descriptive statistics were used to summarize the results, and ordinal regression analysis was employed to assess the factors influencing the severity of LUTS. Results The prevalence of LUTS in the study population was 57.8%, with mild symptoms (mean IPSS 3.92 ± 1.92) being the most common manifestation. The mean age of the study participants who presented with LUTS was 47.89 ± 12.05 years, and the majority were females (55.6%). Factors that were significantly associated with increased severity of LUTS included male sex (OR 2.75; 95% CI 1.59–4.75; p < 0.001), age above 49 years (OR 3.02; 95% CI 1.49–6.16; p = 0.002), ART use for over 10 years (OR 3.03; 95% CI 0.9–6.10; p = 0.021), and HIV stage IV (OR 2.42; 95% CI 0.9–3.4; p = 0.047). The majority of the study participants reported an above-average QoL, with only 9.7% of them reporting unhappy-terrible experiences with urinary symptoms. However, a statistically significant (p < 0.001) inverse correlation between QoL and the severity of LUTS was observed. Conclusions In light of these findings, policymakers and healthcare providers should integrate routine assessment and management of LUTS into the care protocols tailored for these high-risk groups. This proactive approach holds the potential to enhance the QoL and overall welfare of people living with HIV.","PeriodicalId":7432,"journal":{"name":"African Journal of Urology","volume":"22 17","pages":"0"},"PeriodicalIF":0.5000,"publicationDate":"2023-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Investigating bothersome lower urinary tract symptoms among people living with HIV on antiretroviral therapy: prevalence, influencing factors, and quality-of-life implications\",\"authors\":\"Imane H. S. Benyamina, Obadia V. Nyongole, Fransia A. Mushi, Daniel W. Kitua, Aubrey Otieno, Ally H. Mwanga\",\"doi\":\"10.1186/s12301-023-00394-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract Background Urological complications are not uncommon among people living with HIV and are often the initial clinical manifestation of HIV and AIDS. These complications, when presenting with bothersome lower urinary tract symptoms (LUTS), can significantly impact the Quality of life (QoL) of affected individuals. We, therefore, conducted a study aiming at determining the prevalence of bothersome LUTS, identifying factors influencing the severity of these symptoms, and examining their influence on the QoL among people living with HIV on antiretroviral treatment (ART). Methods A cross-sectional study was conducted among randomly selected adult HIV-positive patients who attended the Care and Treatment Center at Muhimbili National Hospital, located in Dar es Salaam, Tanzania, from September 2021 to February 2022. Data was collected using a questionnaire that incorporated the American version of the International Prostate Symptom Score (IPSS). The IPSS was utilized to assess the severity of LUTS and their influence on the QoL. Descriptive statistics were used to summarize the results, and ordinal regression analysis was employed to assess the factors influencing the severity of LUTS. Results The prevalence of LUTS in the study population was 57.8%, with mild symptoms (mean IPSS 3.92 ± 1.92) being the most common manifestation. The mean age of the study participants who presented with LUTS was 47.89 ± 12.05 years, and the majority were females (55.6%). Factors that were significantly associated with increased severity of LUTS included male sex (OR 2.75; 95% CI 1.59–4.75; p < 0.001), age above 49 years (OR 3.02; 95% CI 1.49–6.16; p = 0.002), ART use for over 10 years (OR 3.03; 95% CI 0.9–6.10; p = 0.021), and HIV stage IV (OR 2.42; 95% CI 0.9–3.4; p = 0.047). The majority of the study participants reported an above-average QoL, with only 9.7% of them reporting unhappy-terrible experiences with urinary symptoms. However, a statistically significant (p < 0.001) inverse correlation between QoL and the severity of LUTS was observed. Conclusions In light of these findings, policymakers and healthcare providers should integrate routine assessment and management of LUTS into the care protocols tailored for these high-risk groups. This proactive approach holds the potential to enhance the QoL and overall welfare of people living with HIV.\",\"PeriodicalId\":7432,\"journal\":{\"name\":\"African Journal of Urology\",\"volume\":\"22 17\",\"pages\":\"0\"},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2023-11-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"African Journal of Urology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s12301-023-00394-y\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"African Journal of Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s12301-023-00394-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景泌尿系统并发症在HIV感染者中并不少见,往往是HIV和AIDS的初始临床表现。这些并发症,当出现麻烦的下尿路症状(LUTS)时,可以显著影响患者的生活质量(QoL)。因此,我们进行了一项研究,旨在确定令人烦恼的LUTS的患病率,确定影响这些症状严重程度的因素,并检查它们对接受抗逆转录病毒治疗(ART)的艾滋病毒感染者生活质量的影响。方法在2021年9月至2022年2月期间,随机选择在坦桑尼亚达累斯萨拉姆Muhimbili国立医院护理和治疗中心就诊的成年艾滋病毒阳性患者进行横断面研究。数据的收集采用了美国版的国际前列腺症状评分(IPSS)问卷。IPSS用于评估LUTS的严重程度及其对生活质量的影响。采用描述性统计对结果进行总结,并采用有序回归分析评估影响LUTS严重程度的因素。结果研究人群中LUTS患病率为57.8%,以轻度症状(平均IPSS 3.92±1.92)为最常见的表现。出现LUTS的研究参与者的平均年龄为47.89±12.05岁,大多数为女性(55.6%)。与LUTS严重程度增加显著相关的因素包括男性(OR 2.75;95% ci 1.59-4.75;p & lt;0.001),年龄大于49岁(OR 3.02;95% ci 1.49-6.16;p = 0.002),使用抗逆转录病毒治疗超过10年(OR 3.03;95% ci 0.9-6.10;p = 0.021)和HIV IV期(OR 2.42;95% ci 0.9-3.4;P = 0.047)。大多数研究参与者报告了高于平均水平的生活质量,只有9.7%的人报告了泌尿系统症状的不愉快经历。然而,统计学上显著(p <0.001),生活质量与LUTS严重程度呈负相关。根据这些发现,决策者和卫生保健提供者应将LUTS的常规评估和管理纳入为这些高危人群量身定制的护理方案中。这种积极主动的方法有可能提高艾滋病毒感染者的生活质量和整体福利。
Investigating bothersome lower urinary tract symptoms among people living with HIV on antiretroviral therapy: prevalence, influencing factors, and quality-of-life implications
Abstract Background Urological complications are not uncommon among people living with HIV and are often the initial clinical manifestation of HIV and AIDS. These complications, when presenting with bothersome lower urinary tract symptoms (LUTS), can significantly impact the Quality of life (QoL) of affected individuals. We, therefore, conducted a study aiming at determining the prevalence of bothersome LUTS, identifying factors influencing the severity of these symptoms, and examining their influence on the QoL among people living with HIV on antiretroviral treatment (ART). Methods A cross-sectional study was conducted among randomly selected adult HIV-positive patients who attended the Care and Treatment Center at Muhimbili National Hospital, located in Dar es Salaam, Tanzania, from September 2021 to February 2022. Data was collected using a questionnaire that incorporated the American version of the International Prostate Symptom Score (IPSS). The IPSS was utilized to assess the severity of LUTS and their influence on the QoL. Descriptive statistics were used to summarize the results, and ordinal regression analysis was employed to assess the factors influencing the severity of LUTS. Results The prevalence of LUTS in the study population was 57.8%, with mild symptoms (mean IPSS 3.92 ± 1.92) being the most common manifestation. The mean age of the study participants who presented with LUTS was 47.89 ± 12.05 years, and the majority were females (55.6%). Factors that were significantly associated with increased severity of LUTS included male sex (OR 2.75; 95% CI 1.59–4.75; p < 0.001), age above 49 years (OR 3.02; 95% CI 1.49–6.16; p = 0.002), ART use for over 10 years (OR 3.03; 95% CI 0.9–6.10; p = 0.021), and HIV stage IV (OR 2.42; 95% CI 0.9–3.4; p = 0.047). The majority of the study participants reported an above-average QoL, with only 9.7% of them reporting unhappy-terrible experiences with urinary symptoms. However, a statistically significant (p < 0.001) inverse correlation between QoL and the severity of LUTS was observed. Conclusions In light of these findings, policymakers and healthcare providers should integrate routine assessment and management of LUTS into the care protocols tailored for these high-risk groups. This proactive approach holds the potential to enhance the QoL and overall welfare of people living with HIV.